Antibody landscape against SARS-CoV-2 proteome revealed significant differences between non-structural/ accessory proteins and structural proteins - Li, Yang; Xu, Zhaowei; Lei, Qing; Lai, Dan-yun; Hou, Hongyan; Jiang, He-wei; Zheng, Yun-xiao; Wang, Xue-ning; Wu, Jiaoxiang; Ma, Ming-liang; Zhang, Bo; Chen, Hong; et al. (medRxiv, 2020)
The immunogenicity of SARS-CoV-2 proteome is largely unknown, especially for non-structural proteins and accessory proteins. Here we collected 2,360 COVID-19 sera and 601 control sera. We analyzed these sera on a protein microarray with 20 proteins of SARS-CoV-2, built an antibody response landscape for IgG and IgM. We found that non-structural proteins and accessory proteins NSP1, NSP7, NSP8, RdRp, ORF3b and ORF9b elicit prevalent IgG responses. The IgG patterns and dynamic of non-structural/ accessory proteins are different from that of S and N protein. The IgG responses against these 6 proteins are associated with disease severity and clinical outcome and declined sharply about 20 days after symptom onset. In non-survivors, sharp decrease of IgG antibodies against S1 and N protein before death was observed. The global antibody responses to non-structural/ accessory proteins revealed here may facilitate deeper understanding of SARS-CoV-2 immunology.HighlightsAn antibody response landscape against SARS-CoV-2 proteome was constructedNon-structural/accessory proteins elicit prevalent antibody responses but likely through a different mechanism to that of structural proteinsIgG antibodies against non-structural/accessory proteins are more associated with disease severity and clinical outcomeFor non-survivors, the levels of IgG antibodies against S1 and N decline significantly before deathCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementThis work was partially supported by the National Key Research and Development Program of China Grant (No. 2016YFA0500600), National Natural Science Foundation of China (No. 31970130, 31600672, 31670831, 31370813, 31900112 and 21907065).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (ITJ-C20200128).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 proteome microarray data are deposited on Protein Microarray Database under the accession number PMDE243 (http://www.proteinmicroarray.cn). Additional data related to this paper may be requested from the authors. http://www.proteinmicroarray.cn